India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine for COVID-19, CORBEVAX, developed by Biological E Limited, has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI)for 12-18 years age group.
About:
CORBEVAXTM is a 2-dose vaccine administered intramuscularly and can be stored at 2ºC to 8ºC.
The recombinant protein sub-unit vaccine developed from the Receptor Biding Domain (RBD) of the spike protein on the viral surface is adjuvanted with CpG 1018 and alum.
Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953.
Do you know?
The Department of Biotechnology (DBT) through Mission COVID Suraksha launched under AtmaNirbhar Bharat package 3.0 being implemented by BIRAC, is committed to development of safe and efficacious COVID-19 vaccines.
This is the 2nd vaccine supported under the Mission, to have received EUA for the age group of 12-18 years.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
